

Santen Announces Completion of Repurchase of Own Shares

March 25, 2019, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) announced completion of the repurchase of its own shares as stated below. The repurchase was implemented in accordance with Article 156 of the Companies Act (Japan), as applied pursuant to Article 165, paragraph 3.

- | | |
|--|---|
| 1. Class of shares repurchased: | Common shares of Santen |
| 2. Total number of shares repurchased: | 3,837,500 shares |
| 3. Total amount of repurchase: | 6,636,027,349 yen |
| 4. Period of repurchase: | March 1, 2019 to March 22, 2019
(execution date basis) |
| 5. Method of repurchase: | Purchased on the Tokyo Stock Exchange |

(Reference)

1. Details of the resolution at the meeting of the Board of Directors (announced on February 20, 2019)

- | | |
|---|--|
| - Class of shares to be repurchased: | Common shares of Santen |
| - Total number of shares to be repurchased: | Up to 8,144,000 shares
(2.0% of issued shares, excluding treasury shares) |
| - Total amount of repurchase: | Up to 14 billion yen |
| - Period of repurchase: | February 21, 2019 to March 22, 2019 |

2. Total Company's own shares repurchased through March 22, 2019, pursuant to the above Board resolution

- | | |
|---------------------------------------|--------------------|
| - Total number of shares repurchased: | 8,144,000 shares |
| - Total amount of repurchase: | 13,900,605,009 yen |

About Santen

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries. With scientific knowledge and organizational capabilities nurtured over a nearly 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. For more information, please visit Santen's website (www.santen.com).

Santen Forward-looking Statements

Information provided in this press release contains forward-looking statements. The achievement of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

Contact**Christopher Hohman**

General Manager

Corporate Communications Group

Santen Pharmaceutical Co., Ltd.

E-mail: ir@santen.com

Tel: +81-6-4802-9360